Abstract: Analysis of T cell subsets in the spleen during graft-versus-host (GVH) reactions in a fully allogeneic mouse strain combination demonstrated that first CD4+ T cells become activated, and initiate the GVH reaction. Subsequently, CD8+ T cells become involved. Here we show that anti-CD8 treatment on day +3 resulted in a significant increase in survival, while early treatment (day -1 or day +1) did not. Acute GVH reactions were induced (day 0) in lethally irradiated (C57BLI6 x CBA/J)FI (H-2ti) mice by in~venous injection of BALBlc (H-2d) spleen and lymph node cells (3.6 x IO') within 24 h after irradiation. Mice were treated intraperitoneally with a single optimally depleting dose of rat anti-CD8 (YTS 169.4) or untreated. Symptoms of GVHD became obvious 6 days after reconstitution, and mortality started at day 8. The mutual influence of CD4+ and CD8+ T cells in the development of GVHD becomes apparent from our data, and demonstrates that GVHD lethality can be caused by CDS+ T cells as well as by CD4+ T cells.
Introduction
As became clear from allogeneic bone marrow transplantation in animals, mature T cells in the marrow inoculum can cause gr~-versus-bost disease (GVHD).' When these T cells recognize foreign histocompatibility antigens expressed on host tissue, a systemic cellular immune response develops. Both CD4+ and CD8' T cells are involved in GVHD in mice and humans, depending on the MHC or non-MHC differences between donor and recipient. We formerly demonstrated that in the fully allogeneic BALB/c-(C57BL x CBA)Fl strain combination transplantation of purified CD4+ T cells induced lethal GVHD, whereas purified CD8+ T cells did not, suggesting a major role for the CD4+ T cell subset. 2 Flow cytometric analysis of T cell subsets in the spleen of the (C57BL x CBA)Fl recipients early after reconstitution demonstrated a strong increase in the number of CD4' T cells peaking on day 4 or 5. Also the number of CD8+ T cells increased strongly, but consistently peaked l-2 days later. CD8' T cells then became the predominant T cell subset. Since the first signs of acute GVHD became obvious 6 days after reconstitution, we concluded that in this mouse strain combination subsequent waves of CD4+ and CD8+ T cells preceded the development of clinically overt GVHD?
Anti-CD4 treatment given 1 day before reconstitution was able to prevent the development of lethal GVHD, whereas anti-CD8 treatment was not. Flow cytometric analysis of the spleen of the recipient mice after allogeneic reconstitution and anti-CD4 mon~lon~ antibody (n&b) latent revealed that not only was the number of CD4+ T cells reduced, but also the number of CD8+ T cells.4 These data suggest that by virtue of their interleukin 2 (IL-2) production7 the activated CD4+ T cells likely account for the activation and proliferation of the CD8+ T cells. These results do not reveal the role of the CD8+ T cells in the clinical symptoms of GVHD, although our finding that a strong increase in the number of CDS+ T cells preceded the development of overt GVHD suggests that they are importarK
Objective
In this study we further investigated whether our assumption that CD8+ T cells do play an important role in the effector phase of graft-versus-host disease (GVHD) could be affirmed. To this end, we postponed anti-CD8 treatment to days of ongo-Differential effect of anti-CD8 treatment on ongoing GVH reactions in mice 199 ing GVHD and determined the effect on survival as well as on kinetics of T cell subset populations in the spleen by flow cytometry.
Materials, methods and experimental design
GVH reactions were induced in lethally irradiated (10 Gy) (C57BU6 x CBA/J)Fl (H-2b/k) mice by intravenous injection (day 0) of a mixture of 3 x 10' BALB/c (H-2d) spleen cells with 6 x 106 BALB/c lymph node cells within 24 h after irradiation. Mice were' treated with one optimally depleting dose of 200 pg or even 1 mg of highly purified rat anti-CD8 IgG2b mAb (YTS 169.4)5*6 4 h after irradiation, but before the reconstitution (day -l), or on day +l, +3, +5 or +7. Anti-CD4 treatment was performed with 1 mg of YTS 191.1,6 an IgG2b mAb. Mice were examined daily for the development of signs of acute GVHD. Mortality started at day 8. Irradiated control mice reconstituted with syngeneic cells survived >250 days without signs of disease. Radiation controls died between days 10 and 22.
Flow cytometric analyses of the recipient spleen cells were performed 4,5 and 7 days after induction of GVHD. On these days, cell suspensions of recipient spleens were prepared in buffered salt solution. Nucleated cell concentrations were determined with a Coulter Counter model ZBl. From these spleen cell suspensions (10' nucleated cells/ml) 25 lt.1 was used for staining. The background staining was determined by staining with FITC (fluorescein isothiocyanate)-labelled rabbit anti-rat F(ab'), fragments alone. CD3+, CD8+ and CD4+ T cells were determined by direct staining with FITC-labelled KT3, 53-6.72, and H129.19, respectively. Cells were also stained with a phycoerythrin-labelled Thy-l.2 mAb (30H12). Forward and side scatter settings were gated on leucocyte populations excluding red cells and debris. A total of 4000 cells was analyzed for each determination.
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Results
Survival after anti-CDS treatment (200 pg) on day -1, +l or +3
Postponing anti-CD8 treatment of recipients to day 3 after reconstitution, which is the start of the massive proliferation of CD4+ and CDS+ T cells, resulted in a significantly improved survival as compared to treatment on day -1 or day +l and to untreated mice ( Figure 1 ). However, also after postponed anti-CD8 treatment all mice eventually died.
Flow cytometric analys& of T cell subsets in the spleen after tkeatment on day -1
After anti-CD8 treatment on day -1, low numbers of CD8+ T cells were found in the spleen on day 4 as well as on days 5 and 7 compared to untreated mice (Figure 2 ). When mice were treated on day +3 similar results were obtained (Figure 3) . Moreover, more CD4+ T cells were found on days 4, 5 and 7 compared to untreated mice ( Figure 2 ). In Figure 2 the indicated numbers reflect the additional CD4' T cells above the control. Gn day 7 this increase in CD4+ T cells was statistically significant from untreated mice (P < 0.05).
By comparing Figures 2 and 3 , a difference in kinetics of CD4+ T cells was observed at several time points. The increase in CD4+ T cells occurred much more quickly in the experiment depicted in Figure 3 . Already on day 4 a statistically significant increase in CD4+ T cells (7 x 106) was found as compared to untreated mice.
Flow cytometric analysis of T cell subsets in the spleen after treatment on day +3
After anti-CD8 treatment on day +3 very low numbers of CD8' T cells were found on days 4 and 7 ( Figure 3) . Moreover, fewer CD4' T cells were found on days 4 and 7 as compared to treatment on day -1. Half the number and 0.7 times the number of CD4+ T cells (P < 0.05) were found on days 4 and 7, respectively, after treatment on day +3 compared to treatment on day -1. The number of CD4+ T cells on day 4 was comparable with that of untreated mice. A slight but statistically significant increase in the number of CD4+ T cells (P < 0.05) was seen on day 7 compared to untreated mice.
Survival after treatment with a single high dose (1 mg) of anti-CD8 or anti-CD4 mAb on days -1, +3, +5 or +7
Treatment of mice on days -1, +3, +5 or +7 with 1 mg of anti-CD8 mAb demonstrated that only after treatment on day +3 was there a significant improvement in survival ( Figure  4a ). Moreover, treatment with this high dose of anti-CD8 rnAb resulted in a 60% survival at 100 days.
Treatment of mice with a single high dose (1 mg) of anti-CD4 mAb on day -1 or +3 resulted in survival of all mice. Treatment on day +5 or +7 did not have any effect on survival (Figure 4b) .
Discussion
This is a first study describing the kinetics of CD4' and CD8+ T cells during the development of GVHD and the effect of anti-CD8 and anti-CD4 treatment on these kinetics in relation to the progress of the disease. We demonstrate that anti-CD8 treatment of recipients on day 3 after reconstitution resulted in a significantly improved survival as compared to treatment on day -1 or day +l and to untreated mice (Figure 1 ). Treatment postponed to day +5 or +7 after transplantation, however, had no effect on the development of the disease (Figure 4a On days 4 and 7 we found 7 and 5.7 x I@, respectively, more CD4+ T cells in anti-CD8 day -1 treated mice compared to untreated mice. For anti-CD8 day +3 treated mice we found on day 4 a comparable number and, on day 7, 2.6 x 106 more CD4+ T cells compared to untreated mice. These differences were all statistically significant (P < 0.05) (n = 4 for each day and each treatment).
tor phase, and that a beneficial effect on survival can only be observed when the CD8' T cells are depleted at the start of the effector phase. Three possibilities can explain the improved survival after anti-CD8 treatment at day 3. Firstly, it is possible that the CD8+ T cells have a different role in the induction and effector phase of GVHD. Depletion of CD8' T cells, therefore, could have a different effect on survival dependent on the moment of anti-CD8 treatment. Secondly, if a few CD8' T cells 'escape' the depleting effect of the mAb or if the mAb has a short half-life, early injection of the mAb cannot completely prevent the development of effector CDS' T cells at a later stage. Injection of anti-CD8 rnAb 4 days later (day +3), on the other hand, would be expected to result in lower numbers of CD8+ T cells in the effector phase of GVHD. This would be consistent with the observed improvement in survival (Figure 1) . Flow cytometric analyses, however, demonstrated that only few CD8+ T cells escaped from the depleting mAb (Figure 2) . Moreover, after treatment on day -1 an equally low number of CD8' T cells was found on days 4, 5 and 7 ( Figure 2 ) as in mice treated on day +3 (Figure 3) .
A third explanation is focused on the involvement of the CD4+ T cell. We propose that cytokines produced by CD4+ T cells (e.g. IL-2)' are being consumed for activation and proliferation of CD4+ and CD8' T cells in GVHD, but after anti-CD8 treatment just for CD4' T cells alone. This is based on the data of Figure 2 , showing more CD4+ T cells on days 4, 5 and 7 (1.2, 5.5 and 11 x 106, respectively) after anti-CD8 In summary, CDS+ T cells do not escape from the depleting treatment on day -1 than in untreated mice. It is likely that effect of anti-CD8 mAb, at least not during the first 8 days anti-CD8 treatment on day +3 may result in a lower number after injection. Depleting the CD8+ T cells by mAb injection of CD4+ T cells than treatment on day -1 or day +l after shortly before reconstitution results in an increase of the numreconstitution, since until then cytokines are being used for ber of CD4+ T cells. Under these conditions, the CD4+ T cells activation and proliferation of CD4+ T cells as well as CD8' probably can take over the role of the CD8' T cell in the T cells. Experiments were performed to test this hypothesis.
effector phase of GVHD, since no difference in survival was These showed that after treatment on day +3 the number of observed between anti-CD8 treated (day -1 or +l) and untre.-CD4+ T cells was significantly lower than after treatment on ated mice. Anti-CD8 treatment on day +3 after reconstitution day -1 (Figure 3) . Moreover, compared to untreated mice, a shortens the period for the 04' T cells to expand. Thereby slight increase in the number of CD4' T cells was seen on the role of the CD4+ T cells in the effector phase is probably day 7. This increase of CD4+ T cells in combination with the limited and the onset of deaths by GVHD is postponed. The complete absence of CD8' T cells after treatment is probably question arises whether this postponed death is actually caused insufficient to cause death at that particular moment but merely by a subsequent increase in 04" T cells or an activation of postpones GVH lethality (Figure 1 ).
CD8+ T cells by CD4+ T cells once the anti-CD8 mAb is cle-
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ared from the circulation. As treatment with a single high dose (1 mg) of anti-CD8 mAb resulted in 60% survival at 100 days (Figure 4a ), we suggest that the anti-CD8 mAb prevents the activation of CD8+ T cells by CD4+ T cells. Thus the development of clinical symptoms of GVHD is limited. Together these data show the mutual influence of CD4+ and CD8' T cells in the development of GVHD, and demonstrate that GVHD lethality can be caused by CD8+ T cells as well as by CD4+ T cells.
